Always consult with a healthcare provider before starting any new medication or treatment
Prescribing information for approved GLP-1 medications does not list colorectal cancer as a known adverse effect, though the FDA requires ongoing post-marketing surveillance for all novel therapeutic agents
The difference between these outcomes comes down to understanding how these two therapies interact at a biological level, and making one simple adjustment that most providers overlook
Theres also anecdotal feedback suggesting that overall aesthetic results are enhanced, though how much of that is placebo is hard to say without stronger data
For instance, in the STEP 2 trial, nausea from semaglutide rose from 5% at week 1 to 15% by week 13, then decreased to 8% by week 68
Compared to other weight loss methods and medications, semaglutide has shown superior efficacy